Repligen
Repligen is a bioprocessing technology company specializing in filtration and fluid management systems for the biopharmaceutical industry.
Profile
They make specialized filtration and fluid handling systems for biopharmaceutical manufacturing.
Repligen is a bioprocessing technology company specializing in filtration and fluid management systems for the biopharmaceutical industry. Founded in 1981 and headquartered in Waltham, Massachusetts, the company initially focused on protein research tools before pivoting to bioprocessing in the 2000s. Today, Repligen provides upstream and downstream filtration solutions, fluid management systems, and process analytics tools used in the production of biologics, gene therapies, and vaccines.
Their products are designed to improve efficiency, scalability, and reproducibility in biomanufacturing processes. As of Q1 2025, Repligen reported $169 million in revenue, a 10% year-over-year increase, with adjusted operating income up 72%. The company has expanded through strategic acquisitions, including the 2025 purchase of 908 Devices' bioprocessing portfolio to bolster its process analytical technology (PAT) offerings.
Repligen operates globally, with a recent European Training & Innovation Center opening in Breda to support customers. Their financial guidance for 2025 projects $695-720 million in revenue, reflecting 9.5-13.5% organic growth. The company's focus on single-use technologies and process intensification aligns with industry trends toward flexible and continuous biomanufacturing.
Who buys this
- Biopharmaceutical companies producing monoclonal antibodies and other biologics
- Gene therapy and viral vector manufacturers
- Contract development and manufacturing organizations (CDMOs)
- Academic and government research institutions with bioprocessing needs
- Vaccine producers
Strengths and what to watch
Strengths
- Specialized expertise in tangential flow filtration systems for bioprocessing
- Growing portfolio of single-use technologies reducing contamination risks
- Strong financial position with $697 million cash reserves as of Q1 2025
Watch for
- Dependence on biopharma industry capital expenditures which can be cyclical
- Integration risks from recent acquisitions like 908 Devices' bioprocessing unit
- Potential margin pressure from increased competition in filtration systems
Recent moves
- 5mo ago Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report
- 5mo ago Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
- 6mo ago Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
Key Information
- Founded
- 1981
- Headquarters
- Waltham, Massachusetts
Frequently Asked Questions
What does Repligen do?
Repligen specializes in bioprocessing technologies, providing filtration and fluid management systems for biopharmaceutical manufacturing. Their products enhance efficiency and scalability in producing biologics, gene therapies, and vaccines, supporting both upstream and downstream processes.
What types of bioprocessing products does Repligen offer?
Repligen offers upstream and downstream filtration systems, fluid management solutions, and process analytics tools. Their portfolio includes tangential flow filtration and single-use technologies designed to improve reproducibility and reduce contamination risks in biomanufacturing.
Who uses Repligen's bioprocessing technologies?
Repligen serves biopharmaceutical companies, gene therapy manufacturers, CDMOs, vaccine producers, and research institutions. Their solutions are tailored for monoclonal antibody production, viral vector manufacturing, and other biologics development processes.
How has Repligen performed financially?
Repligen reported $169 million in Q1 2025 revenue, a 10% year-over-year increase, with adjusted operating income up 72%. The company projects $695-720 million in 2025 revenue, reflecting 9.5-13.5% organic growth and a strong cash reserve of $697 million.
What are Repligen's recent developments?
Repligen recently opened a European Training & Innovation Center in Breda and acquired 908 Devices' bioprocessing portfolio. These moves expand their global support network and enhance their process analytical technology offerings.
What are the advantages of Repligen's single-use technologies?
Repligen's single-use technologies reduce contamination risks, improve process flexibility, and align with industry trends toward continuous biomanufacturing. These solutions are particularly beneficial for scalable and efficient production of biologics and gene therapies.
Sources
- www.repligen.com — Product portfolio details for upstream filtration systems
- www.repligen.com — Downstream filtration product offerings
- investors.repligen.com — Q1 2025 financial results and business highlights
- investors.repligen.com — European expansion and recent facility opening